Arrowhead Pharmaceuticals (ARWR) announced a $50 million milestone payment was received from Royalty Pharma plc (RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) – Outcomes Trial of olpasiran, being conducted by Amgen (AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sales milestone payments associated with olpasiran.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Biotech Sector: M&A Fuels Renewed Excitement
- Arrowhead begins Phase 1/2a study of ARO-CFB for mediated kidney disease
- Athira Pharma appoints Javier San Martin as Chief Medical Officer
- Arrowhead announces new Phase 2 SHASTA-2 study of plozasiran in SHTG
- Arrowhead begins EAP to avail plozasiran outside of trials for patients with FCS